

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
PPD Biomarker Discovery Sciences, LLC	03/25/2010

RECEIVING PARTY DATA

Name:	Investissement Quebec
Street Address:	1200 de l'Eglise Street
Internal Address:	Suite 500
City:	Ste-Foy, Quebec
State/Country:	CANADA
Postal Code:	G1V 5A3

PROPERTY NUMBERS Total: 13

Property Type	Number
Patent Number:	6873915
Patent Number:	7197401
Patent Number:	6835927
Patent Number:	7087896
Patent Number:	6989100
Application Number:	11339235
Patent Number:	6753135
Patent Number:	6787761
Patent Number:	6936814
Patent Number:	7253404
Patent Number:	6939718
Application Number:	12088228
Application Number:	11551810

CH \$520.00 6873915

CORRESPONDENCE DATA

501138412

**PATENT
 REEL: 024170 FRAME: 0737**

Fax Number: (312)984-7700
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 312-372-2000
Email: chicago_ip_docket@mwe.com, umattsson@mwe.com,
kwalsh@mwe.com
Correspondent Name: Ulrika Mattsson, McDermott Will & Emery
Address Line 1: 227 W. Monroe Street
Address Line 2: Suite 4400
Address Line 4: Chicago, ILLINOIS 60606-5096

ATTORNEY DOCKET NUMBER:	76792-037
-------------------------	-----------

NAME OF SUBMITTER:	Ulrika E. Mattsson
--------------------	--------------------

Total Attachments: 4 source=biomarker#page1.tif source=biomarker#page2.tif source=biomarker#page3.tif source=biomarker#page4.tif
--

**CONFIRMATORY GRANT OF
INTELLECTUAL PROPERTY SECURITY INTEREST**

WHEREAS, PPD Biomarker Discovery Sciences, LLC, a North Carolina limited liability company ("Debtor"), owns the patents and patent applications shown in the attached Schedule A (the "Patents"), and has adopted, used, is using or has the intent to use the marks shown in the attached Schedule B (the "Marks"), for which there are recordations, registrations or applications, as applicable, in the United States Patent and Trademark Office under the numbers shown in the attached Schedule A and Schedule B; and

WHEREAS, Borrower is obligated to Investissement Québec ("Secured Party") pursuant to a certain Security Agreement, dated the date hereof, made by and between Debtor and Secured Party (as may be amended, modified, restated or supplemented from time to time, the "Agreement"); and

WHEREAS, pursuant to the Agreement, Debtor has granted to Secured Party for a security interest in the Patents, Marks, all proceeds of the Patents and the Marks, all rights corresponding to the Patents and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, and all rights corresponding to the Marks, and the goodwill of the business symbolized by the Marks, and the registrations and applications therefor.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby assign unto Secured Party and grant to Secured Party a security interest in and to (a) the Patents, and recordings and applications therefor, and (b) the Marks, together with the goodwill of the business symbolized by the Marks, and the registrations and applications therefor, which assignment and security interest, in all cases, shall secure all the Obligations (as defined in the Agreement) and in accordance with the terms and provisions thereof. Additionally, all such terms and provisions of the Agreement are herein incorporated by reference and in the event that this Confirmatory Grant of Intellectual Property Security Interest is deemed to conflict with the Agreement, the terms of the Agreement shall govern.

[Remainder of Page Intentionally Left Blank]

Debtor expressly acknowledges and affirms that the rights and remedies of Secured Party with respect to the assignment and security interest granted hereby are more fully set forth in the Agreement.

Dated: March 25, 2010

PPD BIOMARKER DISCOVERY SCIENCES, LLC

By: Caprion Proteomics Inc.

By: 

Name: Stefano Bazzocchi

Its: Vice President and Secretary

**SCHEDULE A
PATENTS**

US	6,873,915	10/226,090	03-29-2005	08-22-2002	Peak Selection In Multidimensional Data	Granted
US	7,197,401	11/075,370	03-27-2007	03-07-2005	Peak Selection In Multidimensional Data	Granted
US	6,835,927	10/272,425	12-28-2004	10-15-2002	Mass Spectrometric Quantification Of Chemical Mixture Components	Granted
US	7,087,896	11/023,234	08-08-2006	12-27-2004	Mass Spectrometric Quantification Of Chemical Mixture Components	Granted
US	6,989,100	10/435,581	01-24-2006	05-09-2003	Methods For Time-Alignment Of Liquid Chromatography-Mass Spectrometry Data	Granted
US	N/A; Div of 6,989,100	11/339,235	N/A	01-24-2006	Methods For Time-Alignment Of Liquid Chromatography-Mass Spectrometry Data	Pending
US	6,753,135	09/956,757	06-22-2004	09-20-2001	Biological Markers for Evaluating Therapeutic Treatment of Inflammatory and Autoimmune Disorders	Granted
US	6,787,761	09/994,575	09-07-2004	11-27-2001	Median Filter For Liquid Chromatography-Mass Spectrometry Data	Granted
US	6,936,814; con of 6,787,761	10/935,562	08-30-2005	09-07-2004	Median Filter For Liquid Chromatography-Mass Spectrometry Data	Granted
US	7,253,404; con of 6,936,814	11/173,937	08-07-2007	07-01-2005	MEDIAN FILTER FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY DATA	Granted
US	6,939,718	10/044,310	09-06-2005	01-11-2002	Mass Spectrometry of Prostaglandins	Granted
US	N/A	12/088,228	N/A	03-26-2008	Biomarkers for Multiple Sclerosis and Methods of Use Thereof	Pending
EP	N/A	EP 0681571.4	N/A	09-29-2006	Biomarkers for Multiple Sclerosis and Methods of Use Thereof	Pending
US	N/A	11/551,810	N/A	10-23-2006	Compositions and Methods Relating to CNS Lymphoma	Pending

Schedule A

CI1199 5229371-2.076792.0037

**SCHEDULE B
MARKS**

None

Schedule B

CI8899 5229371-2,076792.0037

RECORDED: 04/02/2010

**PATENT
REEL: 024170 FRAME: 0742**